0W4N fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
0W4N does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company